Gunderson Dettmer served as lead counsel to WindMIL Therapeutics in its $32.5 million Series B financing round led by Qiming Venture Partners USA with participation from Medivate Partners, Camden Partners Nexus, Domain Associates and FOXKISER.

The Gunderson Dettmer deal team was led by corporate partner Timothy Ehrlich as well as founding partner Jay Hachigian, intellectual property associate Nathan Burk and corporate and securities associates David Horne and Christopher Warren.

WindMIL Therapeutics is developing cell therapies for oncology indications.

For further details, the press release can be seen here.